Stockwinners Market Radar for February 13, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:22 EST Mitek Systems discloses Nasdaq listing notice - Mitek Systems "reported that it received an additional Staff Determination from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that the Company is not in compliance with Nasdaq Listing Rule 5250(c), as a result of the Company's failure to file its Quarterly Report on Form 10-Q for the quarter ended December 31, 2023 in a timely manner, which serves as an additional basis for delisting the Company's securities from Nasdaq. The Company remains delinquent in filing its Form 10-K for the year ended September 30, 2023. The Rule requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission. The Company previously reported in Forms 12b-25 filed with the SEC on December 15, 2023 and February 9, 2024, that the Company was unable to file the Form 10-K and Form 10-Q within the prescribed time period without unreasonable effort or expense. In response to the Staff Determination, the Company intends to file the Form 10-K and Form 10-Q as promptly as possible in order to regain compliance with the Rule."

20:07 EST Cathie Wood's ARK Investment bought 519K shares of Recursion Pharmaceuticals

19:50 EST Precision BioSciences trading halted, news pending

19:50 EST E-Home Household Service Holdings Ltd trading halted, news pending

19:45 EST VF Corp. aligns with Engaged Capital, names Caroline Brown to board - VF Corp. announced the appointment of Caroline Brown to the company's Board of Directors, effective February 14, 2024. This appointment follows constructive engagement with VF's shareholders, including Engaged Capital, LLC. VF also intends to appoint to the Board another independent director in the near term mutually agreed with Engaged Capital, and will give priority to considering the candidates who have been identified by Engaged Capital. VF expects Ms. Brown and the Additional Director will be nominated at VF's 2024 Annual Meeting of Shareholders and at the conclusion of the Annual Meeting, VF's Board will comprise 13 directors, including no more than 11 of VF's current directors.

18:54 EST Abbott announces FDA voted in favor of its TriClip System - Abbott announced that the Circulatory System Devices Panel of the Medical Devices Advisory Committee for the FDA confirmed 13 to 1, with 0 abstention that the benefits of Abbott's TriClip transcatheter edge-to-edge repair, or TEER, system outweighed the risks for the treatment of people with tricuspid regurgitation, or TR. The panel's decision was based on clinical data from the TRILUMINATE pivotal trial, as well as expert testimony. The panel's vote will be considered by the FDA when making a decision regarding the approval of TriClip, a first-of-its-kind minimally invasive device specifically designed to treat the difficult-to-access tricuspid valve. The tricuspid valve controls blood as it flows from the heart's right atrium to the right ventricle. TR occurs when the valve doesn't close properly, causing a leak and allowing blood to flow backward in the heart. For those who continue to have symptoms or persistent TR despite treatment with medical therapy and are not considered good candidates for surgery, TriClip represents a potentially new option that can improve a person's quality of life. Delivered through a vein in the leg, TriClip's TEER technology works by clipping together a portion of the leaflets - or flaps of tissue - to repair the tricuspid valve and help blood flow in the right direction without the need for open-heart surgery. After reviewing data from Abbott's TRILUMINATE pivotal trial and listening to testimony, the panel voted on the device's safety, effectiveness and risk/benefit profile as a treatment for TR. On the question of whether there is enough data to support the safety of the device, the vote was 14 to 0 in favor. On the separate question of whether there is reasonable assurance that the device is effective, the vote was 12 to 2 in favor. On the final question of the benefit of TriClip versus the risk, the vote was 13 to 1 in favor.

17:48 EST Eversource announces sales agreement with Global Infrastructure Partners - Eversource Energy announced it has executed a definitive agreement to sell its 50% ownership share in South Fork Wind and Revolution Wind to Global Infrastructure Partners, or GIP. The transaction allows Eversource to realize approximately $1.1B of cash proceeds upon closing and to exit these projects while retaining certain cost sharing obligations for the construction of Revolution Wind. These cost sharing obligations provide that Eversource would share equally with GIP in GIP's funding obligations for up to approximately $240M of incremental capital expenditure overruns incurred, after which GIP's obligations for any additional capital expenditure overruns would be borne by Eversource consistent with the existing joint venture terms. In addition, around the time of commercial operation of Revolution Wind and closing for South Fork Wind, Eversource's financial exposure will be adjusted after taking into account the updated project economics. Commercial operation of Revolution Wind is expected in 2025. Since South Fork Wind is expected to enter service before the transaction closes, Eversource's financial ties to South Fork Wind, other than as a tax equity partner, are expected to largely be resolved at closing. Eversource plans to use the proceeds from this sale to repay parent debt. The agreement covers Eversource's 50% share in the 132-megawatt South Fork Wind project and the 704-megawatt Revolution Wind project. Orsted's 50% ownership interests are not affected by today's announcement. Eversource is expected to enter into a separate construction management agreement as a contractor to Revolution Wind to complete the onshore work that is currently underway. Eversource will maintain its previously announced tax equity investment in South Fork Wind.

17:32 EST Apollo Global exec sells $16.37M in common stock - In a regulatory filing, Apollo Global disclosed that its co-president James Zelter sold 150K shares of common stock on February 12th in a total transaction size of $16.37M.

17:07 EST QuidelOrtho expects FY24 Labs business growth mid-to-high single digits - Says Flu market is expected to be between 40M-60M tests. Expects Savanna instrument placements of ~1,000. SG&A is expected to approximate the 2023 exit rate. Sees FY24 non-respiratory revenue $2.3B-$2.34B, respiratory revenue $460M-$730M. Comments taken from investor presentation slides.

17:01 EST Vertex Pharmaceuticals COO Arbuckle sells over $1.8M in shares - Vertex Pharma COO Stuart Arbuckle disclosed in a regulatory filing that he had sold 4,295 shares of stock at $420.24 per share on February 12 for a total transaction amount of $1,804,931.

16:50 EST InterCure provides update on Nir Oz facility in Israel - InterCure provided an additional update regarding the status of its facility in Kibbutz Nir Oz in Israel. The company said, "Since October 7, 2023, war situation was declared by the Israeli government. As of this date, there is limited access to the Southern Israel Site, and parts of the site are being used by the Israel Defense Forces (the "IDF"), including, among others, the IDF's medical corps. The Company has begun the process of restoring the Southern Israel Site, and the restoring efforts are advancing according to its plans. In addition, the Company is working diligently with the Israeli authorities to obtain full compensation for the damages caused by the terrorist attack and the war in Gaza. The Company believes, with high certainty, that it will be entitled for compensation from the Israeli Governmental authorities for all direct and indirect damages suffered, as stated in the Company's press release issued on October 17, 2023. With the leadership position in the medical cannabis market and years of operations with the community of Kibbutz Nir-Oz, the Company is committed to restore and further develop the Southern Israel Site. The Company is also committed to support patients' communities especially, patients living in affected and evacuated areas, casualties and IDF veterans. Bringing relief is our mission statement. Intercure is thankful to its managers and employees for their commitment and to its strategic partners in Israel and worldwide who stand with us in this war time. The Company intends to file preliminary results for the second half of 2023 and for its full year of 2023 through the beginning of March, and to file its full financial results for 2023 during April 2024."

16:47 EST Sana Biotechnology publishes HIP-modified pancreatic islet cells data - Sana Biotechnology announced that Cell Stem Cell has published a paper titled "Hypoimmune islets achieve insulin independence after allogeneic transplantation in a fully immunocompetent non-human primate." The paper evaluated a transplant of Sana's engineered allogeneic, hypoimmune, or HIP-modified pancreatic islet cells into a fully immunocompetent, diabetic non-human primate, or NHP. These modified islet cells, which cluster into effective endocrine organoids, are termed "pseudo islet grafts". The results demonstrated that the HIP-modified p-islets engrafted following intramuscular injection and provided stable endocrine function, enabling insulin independence in the absence of immunosuppression. The transplant setting was purposely designed to be a high immunological bar by maximizing the donor-to-recipient mismatch. Diabetes mellitus was chemically induced in the recipient as shown by the development of major blood glucose instability and the need for daily insulin injections to control blood sugar. Following stabilization of glucose with insulin treatment, the diabetic NHP underwent transplantation of the HIP p-islets without any induction or maintenance immunosuppression and the administration of insulin was tapered to zero over the course of nine days. Rapidly following HIP p-islet transplantation, the diabetic NHP recipient showed tightly controlled blood glucose levels, was completely insulin-independent, continuously healthy, and exhibited no physical or behavioral abnormalities for the six-month study duration. C-peptide levels, which are a marker for endogenous insulin production and release, reached the normal levels observed prior to induction of diabetes. Furthermore, there was no indication that the allogeneic HIP p-islet graft induced any immune recognition or any type of immune response at any time. To demonstrate that there was no regeneration or recovery of an endogenous islet cell population in the diabetic NHP, HIP p-islets were eliminated using an anti-CD47 antibody. The antibody blocked the protective CD47 signal and triggered a "missing self" innate immune cell response that led to the rapid destruction of the HIP p-islet graft. Following the anti-CD47 treatment, blood glucose levels in the diabetic NHP began to fluctuate and increase markedly, and insulin injections needed to be resumed. It was thus demonstrated that the tightly controlled blood glucose levels and insulin independence was entirely due to well-functioning HIP p-islets.

16:42 EST Codexis enters $40M loan facility agreement with Innovatus - Codexis announced it has entered into a loan facility agreement with an affiliate of Innovatus Capital Partners for up to $40M, including $30M upfront and access to an additional $10M upon achieving certain prespecified revenue thresholds. This loan facility reinforces Codexis' cash position and provides additional flexibility to its projected runway through cash-flow positive around the end of 2026. Following the closing of the term loan agreement, Codexis retained approximately $29M in net proceeds from the first tranche. The loan carries an interest-only period of 36 months and a total term of 60 months.

16:40 EST Kratoswins $579M single award IDIQ for Space Force SATCOM C2 System - Kratos Defense & Security Solutions announced that it is the single recipient for the Command and Control C2 System Consolidated CCS-C Sustainment and Resiliency C-SAR indefinite-delivery/indefinite-quantity IDIQ contract with a maximum value of $579M, if all options are exercised. The start date is December 1 with options going to May 31, 2032. Future task/delivery orders will be issued to support operations, sustainment, or enhancements of the CCS-C and related systems.

16:38 EST Campbell Soup, Sovos certify substantial compliance with second FTC request - Campbell Soup (CPB) and Sovos Brands (SOVO) announced that both companies have certified substantial compliance with the Request for Additional Information and Documentary Materials issued by the Federal Trade Commission, or FTC, regarding Campbell's proposed acquisition of Sovos Brands. The certification of substantial compliance triggers the start of a 30-day waiting period which is expected to expire on March 11 after which the sale can be finalized. Subject to the satisfaction or waiver of customary closing conditions, the companies expect to complete the transaction within days of the March 11 expiration date.

16:35 EST Campbell, Sovos certify substantial compliance with second FTC request - Campbell Soup Company (CPB) and Sovos Brands, Inc. (SOVO) announced that both companies have certified substantial compliance with the Request for Additional Information and Documentary Materials issued by the Federal Trade Commission regarding Campbell's proposed acquisition of Sovos Brands. The certification of substantial compliance triggers the start of a 30-day waiting period which is expected to expire on March 11, 2024, after which the sale can be finalized. Subject to the satisfaction or waiver of customary closing conditions, the companies expect to complete the transaction within days of the March 11, 2024 expiration date. "We're excited to be one step closer to completing the acquisition and welcoming the talented Sovos Brands employees to Campbell's team," said Campbell's President and CEO Mark Clouse. "The Sovos Brands portfolio strengthens our Meals & Beverages division, and paired with our fast-growing Snacks division, will create one of the best portfolios in the industry and make Campbell one of the most dependable, growth-oriented names in food."

16:35 EST Upstart Holdings trading resumes

16:28 EST Robinhood jumps 15% to $13.60 after Q4 earnings beat

16:26 EST Instacart raises share repurchase authorization to $1B - On February 9, the Board approved an increase to the company's previously announced share repurchase program, authorizing the purchase of up to an aggregate of $1B of the company's common stock, up from the $500M authorized by the Board in November 2023. Approximately $430M of capacity was remaining under the Previous Share Repurchase Program prior to the increase. The Share Repurchase Program has no expiration date.

16:22 EST Airbnb announces new $6B share buyback authorization - Airbnb said: "Our strong cash flow enabled us to repurchase $750 million of our Class A common stock in Q4 2023. Share repurchases during the full year 2023 totaled $2.25 billion, and we reduced our fully diluted share count from 694 million at the end of Q4 2022 to 676 million at the end of Q4 2023. Since we announced our first share repurchase program in 2022, we have repurchased a total of $3.75 billion of Class A common stock. As of December 31, 2023, we had $750 million remaining under our prior program and today, we're announcing a new share repurchase program with authorization to purchase up to $6 billion of our Class A common stock."

16:21 EST Instacart announces restructuring plan, 7% workforce reduction - On February 9, the Board of Directors of the Company approved restructuring actions with respect to its workforce to improve operational efficiencies and better align the Company's organizational structure with current business needs, top strategic priorities, and key growth opportunities. The Restructuring Plan includes a reduction of approximately 250 employees, representing approximately 7% of the Company's global workforce as of January 31, 2024, with most of these reductions expected to occur by March 31, 2024. Any local separations will be determined at the time and as required by any local consultation or process requirements. The Company estimates it will incur approximately $19 to $24 million in non-recurring charges in connection with the Restructuring Plan, predominantly related to cash expenditures for employee transition and severance payments and employee benefits. Of the total restructuring expenses, $17 to $22 million is expected to result in future cash outlays. The Company expects the majority of the charges to be recognized in the first quarter of 2024. The costs associated with the Restructuring Plan will be included in the Company's GAAP results but are expected to be excluded from the Company's non-GAAP results.

16:14 EST Robinhood reports Q4 monthly active users 10.9M, down 4% - Reports Q4 average revenue per user $81. Reports assets under custody increased 65% year-over-year to $102.6B.

16:07 EST Lyft sees Q1 adjusted EBITDA $50M-$55M - Sees Q1 gross bookings roughly $3.5B-$3.6B.

16:01 EST Upstart Holdings trading halted, news pending

15:13 EST Roku down 10% after Journal report of Walmart talks to buy Vizio

15:12 EST Vizio up 6% after Journal report of Walmart takeover talks

15:07 EST VIZIO Holding Corp trading halted, volatility trading pause

14:46 EST StoneBridge Acquisition Corp trading halted, volatility trading pause

14:40 EST Gryphon Digital reports about 58 bitcoin-equivalent coins produced in January - Gryphon Digital Mining has released its operational update for January 2024. During January, Gryphon mined approximately 58 bitcoin-equivalent coins while posting a company record average self-mining hashing power of 864 PH/s and total attributable hashing power of approximately 1.3 EH/s. "The month's performance translated into a bitcoin efficiency rating of 68 BTC/EH. The company's bitcoin efficiency performance declined from its December 2023 mark of 81 BTC/EH, or a reduction of about 16%. December's performance ranked second among publicly disclosing peers, which averaged 66 BTC/EH for the month," Gryphon stated.

14:37 EST Esports Entertainment delisting from Nasdaq, moving to OTCQB Venture Market - Esports Entertainment Group announced that its board of directors has approved a voluntary delisting of the company's Common Stock, 10.0% Series A Cumulative Redeemable Convertible Preferred Stock and Common Warrants from the Nasdaq Stock Market, which is expected to reduce the company's public costs as it advances its strategy to drive growth and profitability. As a result, the company anticipates that it will file with the Securities and Exchange Commission a Form 25 relating to the delisting of its Securities and expects its Securities will be listed on the OTCQB Venture Market of the OTC Markets, until such time it decides to reapply and is approved to relist on a senior U.S. Exchange. On February 13, when the company informed the Nasdaq of its intention to delist it was under a Nasdaq Panel Monitor and not in compliance with the Nasdaq's stockholders' equity requirement. Alex Igelman, CEO of Esports Entertainment Group, stated, "While we have solid assets inside the business, and have assembled a first-class management and board, the restructuring and turnaround of the business has been no small undertaking. Although we have made substantial and rapid progress, we have several more significant initiatives still underway. At the same time, the expenses related to maintaining our Nasdaq listing are significant, and, despite our listing on a senior U.S. exchange, we do not believe the current market price reflects the intrinsic value of our business. At the moment, we are 100% focused on driving growth and profitability and believe that this move to the OTC Markets will allow us to regroup as we execute on the aforementioned initiatives. In this way, assuming we meet the listing requirements, we could relist on a senior U.S. Exchange at a time of our choosing. In the meantime, we plan to reallocate resources towards activities, some of which we have previously identified, that we believe will generate the highest return on capital and maximum long-term value for our shareholders."

13:54 EST Ribbon announces U.S. military branch voice modernization project - Ribbon Communications (RBBN) announced that it will transition a branch of the U.S. Military's voice infrastructure to Voice over Internet Protocol, or VoIP, ahead of the 2025 deadline mandated by the Department of Defense, in collaboration with Dell Technologies (DELL). "This award highlights our leadership in delivering innovative solutions that improve communications infrastructure while lowering costs and accelerating digitization for the US government, and ultimately the US taxpayer. We're proud to have been selected for this critical project and of our collaboration with a global provider like Dell Technologies," said Bill Grabner, Vice President, Federal Markets from Ribbon.

13:17 EST Polished down 60% after cutting outlook, reporting SEC probe - Shares of Polished.com are down $2.94, or 60%, to $1.92 in early afternoon trading.

12:29 EST Phoenix Biotech Acquisition Corp trading halted, volatility trading pause

12:12 EST PSEG raises quarterly dividend to 60c per share - The Board of Directors of Public Service Enterprise Group declared a 60c per share quarterly common stock dividend for the first quarter of 2024, payable on or before March 29, 2024, to shareholders of record on March 8, 2024. his action represents an increase of 3c per share in the company's quarterly common stock dividend, bringing the 2024 indicative annual rate to $2.40 per share.

12:02 EST Lantheus announces collaboration with NIA-sponsored study called CLARiTI - Lantheus Holdings earlier today announced a collaboration agreement with a National Institute on Aging-sponsored study called the Consortium for Clarity in ADRD Research Through Imaging, or CLARiTI. "This agreement enables the consortium to use MK-6240, Lantheus' clinical-stage F18-labeled Positron Emission Tomography imaging agent, in its investigation of Alzheimer's disease and related dementias. MK-6240 targets aggregated tau protein in the form of neurofibrillary tangles, which are a hallmark of several neurodegenerative diseases, including Alzheimer's disease. The CLARiTI study will involve all 37 Alzheimer's Disease Research Centers in the United States which will recruit 2,000 subjects and collect their imaging and blood-based biomarker data to generate etiologic profiles for cases of mixed dementia," the company stated. "MK-6240 is poised to play a pivotal role in propelling Alzheimer's diagnosis and treatment research to new heights. This agreement aligns with Lantheus' purpose to actively cultivate collaborations that empower researchers worldwide with essential tools to accelerate clinical research and development of therapies. In an era defined by an unprecedented number of Alzheimer's diagnoses, the CLARiTI study represents a significant milestone in Alzheimer's research, with the potential to change the trajectory of this degenerative disease," said Jean-Claude Provost, MD, Chief Medical Officer, Lantheus.

12:00 EST Direxion Daily Junior Gold Miners Index Bear 3x Shares rises 11.6% - Direxion Daily Junior Gold Miners Index Bear 3x Shares is up 11.6%, or 81c to $7.82.

12:00 EST Wesco falls -23.3% - Wesco is down -23.3%, or -$44.81 to $147.72.

12:00 EST Trinseo falls -28.8% - Trinseo is down -28.8%, or -$1.77 to $4.38.

11:49 EST Polished says SEC conducting investigation of prior disclosures - In a regulatory filing, Polished.com stated: "The U.S. Securities Exchange Commission is conducting an investigation related to issues disclosed in the company's Form 8-K filed on December 27, 2022, including the findings of the company's Audit Committee investigation, as described therein, and the subsequent restatement of the company's previously issued consolidated financial statements as of and for the year ended December 31, 2021 and for the quarter ended March 31, 2022. The SEC staff has subpoenaed documents and information, including documents and information related to the Audit Committee's investigation and restated financials. The SEC Investigation is a non-public, fact-finding inquiry to determine whether there were any violations of the federal securities laws. The company is fully cooperating and will continue to cooperate with the SEC." Reference Link

11:23 EST Accenture announces agreement to acquire Insight Sourcing; terms not disclosed - Accenture has entered into an agreement to acquire Insight Sourcing, a provider of strategic sourcing and procurement services. "Insight Sourcing will be the latest investment we are making to address growing demands from private equity investors, who seek tailored and repeatable solutions that drive value," said Muqsit Ashraf, global lead for Accenture Strategy. Terms of the transaction were not disclosed. Completion of the acquisition is subject to customary closing conditions, including receipt of regulatory approvals.

11:15 EST Boeing sees defense margins reaching high single digits by 2025

11:14 EST Boeing CFO: 737 output for 1H24 to be below 38-jets a month pace - Comments taken from the Cowen Aerospace & Defense Conference.

10:30 EST American Electric gives two board seats to Icahn Capital - American Electric Power announced last night that it has entered into an agreement with Icahn Capital and certain of its affiliates, under which Hunter Gary, senior managing director at Icahn Enterprises, and Henry Linginfelter, retired executive vice president of Southern Company Gas, will join AEP's board of directors. Julie Sloat, AEP CEO, said, "On behalf of the Board, we welcome Hunter and Hank to AEP. Hunter's experience providing operational oversight as an investor and public company director and Hank's utility regulatory experience will serve us well as we continue to execute on our strategic priorities and enhance value for our shareholders. We are confident that their perspectives will add value in the boardroom as we continue to simplify and de-risk our operations, control costs and execute on our flexible and robust capital plan to provide safe, reliable and affordable service to our customers." Carl Icahn added, "We look forward to working with Julie Sloat and the Board of Directors to optimize the value and performance of AEP's high quality regulated electric utility business for the benefit of all of AEP's stakeholders." Additionally, the board has invited Andrew Teno, portfolio manager at Icahn Capital, to serve as a non-voting observer in board meetings. Icahn Capital and certain of its affiliates have agreed to customary standstill, voting commitments and other provisions.

10:29 EST Altimmune down 16% after Kerrisdale short report - Shares of Altimmune are down $1.70, or 16%, to $8.70 in morning trading after the company was the subject of a short report published earlier by Kerrisdale Capital.

10:08 EST Carbon Revolution PLC trading resumes

10:03 EST Carbon Revolution PLC trading halted, volatility trading pause

10:02 EST Penn to acquire mobile sports wagering licenses for New York market access - PENN Entertainment, Inc. (PENN) announced that it has reached an agreement with Wynn Interactive Holdings (WYNN) to acquire its New York mobile sports wagering licenses, providing PENN with market access to the jurisdiction. Pending regulatory approvals, PENN will launch its online sports wagering product, ESPN BET, in New York in 2024. As part of the transaction, PENN is acquiring WSI US, LLC, from Wynn Interactive Holdings for $25M. WSI US, LLC is the entity that holds the mobile sports wagering licenses that were previously issued by the New York State Gaming Commission in 2021. Wynn Interactive is a subsidiary of Wynn Resorts, Limited. "This is an important development that will bring ESPN BET to the largest regulated online sports wagering market in North America," said Jay Snowden, PENN Entertainment CEO and President. "Together with ESPN, we're building a brand that is synonymous with sports betting, and operating in the New York market is key as we grow ESPN BET across the U.S."

10:00 EST Wesco falls -19.8% - Wesco is down -19.8%, or -$38.18 to $154.35.

10:00 EST Aspen Aerogels rises 9.1% - Aspen Aerogels is up 9.1%, or $1.13 to $13.53.

10:00 EST Daily S&P Biotech Bear 3x Shares rises 10.7% - Daily S&P Biotech Bear 3x Shares is up 10.7%, or 89c to $9.17.

09:50 EST Delta Apparel trading resumes

09:49 EST GEDi Cube signs LOI to acquire 75% of Cyclomics - GEDi Cube has executed a binding Letter of Intent (LOI) to acquire 75% of Cyclomics, a Dutch Company. Under the terms of the LOI, the parties have agreed to work in good faith on the drafting of a definitive agreement. Cyclomics has developed a groundbreaking diagnostic method for monitoring early cancer recurrence named "CyclomicsSeq"- a novel ctDNA detection assay based on Oxford Nanopore sequencing which delivers fast, low-cost, and point-of-care sequencing. In contrast to available ctDNA-based methods, "CyclomicsSeq" ensures that even a single ctDNA molecule in the blood can be detected at very high accuracy. This solution consists of a new diagnostic kit, which has been licensed to Oxford Nanopore, an RNA/DNA next-generation sequencing platform company. Cyclomics' Omni-Omic 4th generation technology, we believe, will disrupt the cancer diagnostics market and clinical practice by enabling fast and reliable results and delivering superior performance to standard radiological and physical examination alone. The platform is expected to enable reliable, fast, and ultra-sensitive early/recurrence detection of cancer using the next-generation whole genome sequencing. That is achieved by detecting ctDNA, a reliable biomarker for determining the presence or absence of cancer, which can be non-invasively obtained from a blood sample. The novel approach to cancer detection is based on a single vial of blood and multi-dimensional profiling. Cyclomics applies a wide multi-signal/multi-omics approach to a very low amount of tumor ctDNA. The Omni-Omic approach is critical for early cancer detection with high accuracy. Upon closing, the combined companies will aim to accelerate entry into the cancer monitoring market and gain access to integrating whole genome data into GEDiCube's AI/Machine Learning platform.

09:48 EST Renovaro sinks 20% after Hindenburg announces short position

09:47 EST Berry Global opens 'Circular Innovation and Training Center' in Oklahoma - Berry Global recently opened the doors to its "Circular Innovation and Training Center" in Tulsa, Oklahoma. The new 12,000 square foot center will accelerate the development of highly innovative products driven by superior materials science and engineering, foster a collaborative space for training, and incubate cutting-edge stretch film projects that help keep materials in use and out of the environment. Stretch films are made with thin, light-weight, extruded plastic and wrapped around a product to achieve load integrity. This promotes sustainability by eliminating or reducing breakage, damage, and loss of products during shipment. Showcasing a range of state-of-the-art pallet wrapping machines and film evaluation equipment, Berry's new center will spur the development of new Bmore Circular Solutions across ultra-high-performance films that support a circular economy through the use of recycled content, material downgauging, and more. Lighter weight stretch films require less raw materials and energy to produce, thereby reducing greenhouse gas emissions and plastic waste.

09:47 EST Teradata falls -20.4% - Teradata is down -20.4%, or -$9.93 to $38.86.

09:47 EST Direxion Daily Semiconductor Bear 3X Shares rises 9.0% - Direxion Daily Semiconductor Bear 3X Shares is up 9.0%, or 39c to $4.73.

09:47 EST Daily S&P Biotech Bear 3x Shares rises 10.6% - Daily S&P Biotech Bear 3x Shares is up 10.6%, or 88c to $9.16.

09:44 EST Rail Vision Ltd trading halted, volatility trading pause

09:43 EST Larimar Therapeutics trading halted, volatility trading pause

09:41 EST SSR Mining trading resumes

09:38 EST MicroCloud Hologram Inc trading halted, volatility trading pause

09:37 EST Exponential Markets receives strategic investment from Citi - Exponential Markets announced a strategic investment from Citi to develop and launch innovative risk mitigation tools. Citi invested in Exponential's most recent seed round, which was led by MaC Venture Capital, and included support from Autotech Ventures and Avanta Ventures, bringing the total amount raised to over $10 million. Citi made the investment through its Markets Strategic Investments unit. The investment and partnership underscores Citi's commitment to furthering the development of innovative risk mitigation tools. Exponential Markets is developing a series of next-generation tradable financial instruments designed to offer new levels of hedging capabilities and risk management for participants in a variety of asset classes. The company's first product, the Exponential Used Vehicle Index, is a first-of-its-kind tradable index for the automotive sector that allows rental car companies, auto insurers, and auto lessors to hedge used vehicle price risk. The company's product roadmap includes cash-settled index derivatives for new and underserved markets, in addition to exploration of smart market applications. In addition to the investment, Citi intends to collaborate with Exponential to cultivate the market for Exponential's used vehicle derivatives, as well as jointly develop new products that will enable more efficient risk transfer across a variety of asset classes, industries, and market participants.

09:36 EST Beamr Imaging Ltd trading resumes

09:35 EST BanCoppel partners with Western Union to receive remittances via mobile app - BanCoppel and Western Union announced a new service for customers in Mexico to receive remittances digitally. Through the BanCoppel mobile app, which is available for Android and iOS, customers who receive cash remittances up to $2,999 per day and $3,000 per calendar month from abroad will be able to deposit them in their BanCoppel bank account. This new service is part of the long-standing collaboration established in 2013 for BanCoppel to offer Western Union global money transfer services. To access it, customers in Mexico must have an active account and a digital services agreement with BanCoppel, which they can set up at any local BanCoppel branch in the country.

09:33 EST GlucoTrack appoints Luis Malave as chairman of the board - Glucotrack announced that Luis Malave has been elected as Chairman of its Board of Directors, effective immediately. Malave currently serves as President of EOFLOW CO. Ltd., a company listed on the Korea Stock Exchange that has developed a wearable disposable insulin pump.

09:31 EST Beamr Imaging Ltd trading halted, volatility trading pause

09:28 EST WidePoint trading halted, news pending

09:26 EST Vox Royalty to acquire Australian royalty portfolio for A$4.7M - Vox Royalty has executed a binding agreement dated February 12, 2024, to acquire a portfolio of up to four royalties at various stages of development including: construction, development and exploration stages and the rights to one production-linked milestone payment, all located in Australia, from a private Australian group, for cash consideration of up to A$4,700,000. Transaction Highlights: Addition of up to four advanced Australian royalties and the rights to one production-linked milestone payment in Western Australia and New South Wales, heavily weighted to gold and copper; Potential for near-term revenue from the construction-stage Castle Hill gold project in Western Australia, operated by Evolution Mining, which is a key part of the A$250M Mungari Mine Life Extension project and mill expansion to 4.2Mtpa announced by Evolution on 5 June 2023; Further production potential from the past-producing Kunanalling gold project, which is located less than 15km from the Mungari Mill and also part of Evolution's integrated Mungari 4.2 Project;Provides critical metals exposure to copper, cobalt and rare earth metals across the Halls Creek and Broken Hill exploration projects; and Strengthens Vox's proportion of royalty assets located in lower risk political jurisdictions of Australia, Canada and USA, totalling more than 80% of all royalty assets. Closing of the Transaction is expected to occur prior to the end of Q1 2024, following satisfaction of customary conditions as well as execution and delivery of standard transaction documentation. Vox will use current cash on hand to fund the payment of the cash consideration for the Transaction. A number of royalties in the portfolio are subject to rights of first refusal, which are typical for the transfer of royalties of this nature.

09:20 EST Kartoon Studios announces record revenue, subscriber growth in Q4 - Kartoon Studios announced its streaming service business, which premiered in June 2020, has achieved record revenue, increased its paid subscribers, expanded its international market coverage and reached break-even EBITDA in the fourth quarter of 2024. Kartoon Channel! has steadily grown to become a pre-eminent children's entertainment destination that delivers thousands of episodes of carefully curated, and family-friendly content. In 2023, paid subscribers increased 19% over 2022, in contrast to a number of streaming services that have been experiencing declines. Importantly, free trials, a leading indicator for future growth, more than doubled in Q4 2023 compared to the same period in 2022. Kartoon Studios' streaming business recently hit break-even for the latest quarter, a notable accomplishment among streaming services, many of which have struggled with losses. In addition, the Company has successfully reduced its customer acquisition costs by 50% from the first half to the second half of 2023, driving bigger margins through improved media efficiency and a successful content strategy. In the Apple app store, Kartoon Channel! continues to sustain a top rating, 4.9 out of 5 stars, outperforming major competitors, including Netflix, YouTube Kids, and Disney+.

09:13 EST Masimo announces FDA-cleared 'over-the-counter' fingertip pulse oximeter - Masimo announced FDA clearance of MightySat Medical, making it the first and only FDA-cleared medical fingertip pulse oximeter available Over-The-Counter OTC direct to consumers without a prescription. All other pulse oximeters available at drug stores and online and sold direct to consumers are not FDA cleared and should not be relied upon for medical use; many of them have been reported to give erroneous measurements.1 This clearance brings consumers a pulse oximeter medical device powered by Masimo SET pulse oximetry-the same technology relied on by hospitals and clinics around the world to monitor more than 200 million patients every year2 and shown to have no clinically significant difference in accuracy or bias between light- and dark-skinned individuals.3 Starting today, the MightySat Medical Pulse Oximeter can be purchased at masimo.com, and it will soon be available for purchase at retail and drug stores across the country.

09:10 EST Anika Therapeutics announces highlighting recently-launched products - Anika Therapeutics announced it is highlighting recently-launched products in high growth segments of joint preservation and restoration from its Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions businesses during the 2024 American Academy of Orthopedic Surgeons Annual Meeting on February 13-15 in San Francisco, CA. "We're thrilled to once again participate in the AAOS 2024 Annual Meeting and to showcase our advanced portfolio of regenerative, sports medicine and bone preserving implant solutions designed to meet the evolving needs of surgeons across the orthopedic continuum of care," said Cheryl Blanchard, Ph.D., Anika's President and CEO. "Anika is excited to highlight our recently launched Integrity Implant System, our newest regenerative hyaluronic acid-based scaffold for rotator cuff repair, and our X-Twist Fixation System with biocomposite suture anchor. We have also enhanced our shoulder arthroplasty offerings with the launch of AIM, Anika Implant Management, for 3-D preoperative planning which is now available with both the RevoMotion Reverse Shoulder and OVOMotion Total Shoulder arthroplasty systems.."

09:08 EST Sprout Social launches new care solution - Sprout Social announces the launch of Social Customer Care by Sprout Social, advancing the platform's care offering with comprehensive case management solutions, AI-powered capabilities and robust reporting. Care by Sprout empowers brands to provide exceptional customer experiences and drive lasting loyalty with fast and meaningful customer engagement. "Social is no longer just one aspect of customer care, it's the determining factor of an impactful care strategy and, more importantly, lasting brand success," said Justyn Howard, CEO of Sprout Social. "Consumer expectations on social media are skyrocketing, and a brand's ability to provide quick, personalized responses across social platforms is critical to meeting and exceeding those needs. This has placed growing pressure on an organization's care team, and we've been focused on delivering a platform that not only supports their efforts, but inspires their strategies and creates immense competitive advantage."

09:07 EST Rumble says Second Circuit to hear oral argument in free speech case on Friday - On February 16, the United States Court of Appeals for the Second Circuit will hear oral argument on behalf of First Amendment professor and legal blogger Eugene Volokh and social media platforms Rumble and Locals. Volokh, Rumble, and Locals are represented by attorneys from the Foundation for Individual Rights and Expression, a national free speech group. In December 2022, Volokh, Rumble, and Locals sued the state of New York after it enacted a law that forces websites to "respond [to]," "address" and "handle" protected speech that someone, somewhere finds "humiliating" or "vilifying" toward a group based on race, color, religion, or other protected categories. A federal judge ruled that New York's law was likely unlawful, and after FIRE won an injunction against the law, New York appealed to the Second Circuit.

09:06 EST Saga Communications agrees to assets from Neuhoff Communications - Saga Communications announced that it has entered into an agreement to purchase the assets of WKOA, WKHY, WASK, WXXB, WASK and W269DJ from Neuhoff Communications, Inc. serving the Greater Lafayette, IN radio market. Chris Forgy, President and Chief Executive Officer of Saga Communications, said, "We regretted missing the opportunity to acquire these stations a number of years ago when the Neuhoff family acquired them. These stations are a great fit for Saga. We see a lot of opportunity with these stations and this market and are pleased that the family has decided to entrust Saga with continuing these station's long-standing heritage of serving the Greater Lafayette region. Saga intends to continue building its business in radio by identifying and acquiring middle market stations in dynamic communities."

09:04 EST NeuroMetrix announces review of strategic options to promote growth - NeuroMetrix announced a process to review strategic options to promote growth of its Quell neuromodulation and DPNCheck neurodiagnostic businesses and to maximize shareholder value. The Company plans to consider a wide range of options, including changes in marketing strategies, the acquisition of new assets, potential sale of Company assets, and merger or other strategic transactions. As the Company explores these strategic options there will be no change in the Company's commercial operations. The Company has engaged Ladenburg Thalmann & Co. as its financial advisor to assist in this process. There can be no assurance that this process will result in the Company pursuing or consummating any particular transaction or other strategic outcome. The Company has not set a timetable for completion of this evaluation process and may not disclose further developments unless disclosure is appropriate or necessary.

09:02 EST Western Uranium & Vanadium provides strategic goals for 2024 - Western Uranium & Vanadium offers an update on its mining operations, highlighting significant achievements and outlining strategic goals for the upcoming year. The company said, "Throughout 2023, the Sunday Mine Complex project witnessed exceptional progress, exceeding expectations in various facets. Key milestones include the identification of previously unknown large ore deposits, the successful development of the GMG ore body, and the establishment of an in-house mining capability. The success at the GMG ore body is also advantageous for the DV ore body which is situated on trend beyond the GMG. Moreover, the identification of additional mineralized areas while drifting has bolstered exploration prospects that are accessible from the St. Jude Mine workings. Looking forward, the Company is gearing up to produce significant quantities of uranium and vanadium in 2025. This ambitious goal hinges on achieving a daily ore production of 500 tons, with an anticipated yield of approximately 3,000 pounds of uranium per day. A successful ramp-up would achieve the annual ore production goal of 1 million pounds of uranium and 6 million pounds of vanadium. To support these objectives, our mining team commenced the year with the expansion of infrastructure into deeper areas of the Sunday Mine Complex. The expansion encompassed electric, water, air, and phone utilities. This project facilitates simultaneous ore sourcing from separate target areas and optimizes throughput via multiple haulage pathways. Our next major target, the Leonard & Clark ore body is accessible from the West Sunday Mine and is approximately 2,700 feet away from the nearest existing underground mine area. Two alternating mining crews operating seven days a week are driving a drift which we anticipate to reach target by fall 2024. In 2024, our primary drilling objective is to define additional mining areas utilizing underground horizontal drilling. This cost-effective alternative to surface drilling aims to identify new high-value targets for mine development and support an ore resource upgrade program, defining additional resources for a NI 43-101 technical report. Notably, longhole and shorthole drilling efforts have already commenced on mineralized areas encountered while drifting to the GMG ore body. Additional drilling will target extensive unexplored areas of the project. Western is actively seeking to double our drilling capacity by adding a second drill team. Favorable market conditions in the uranium sector, characterized by increased price levels, bolster our plans to expedite mine development and enhance production capacity. Our current production ramp-up efforts are geared towards ensuring an adequate uranium feedstock supply for the Maverick Minerals Processing Plant."

09:00 EST SSR Mining suspends operations at Copler mine - SSR Mining announced a suspension of operations at the Copler mine as a result of a large slip on the heap leach pad. This event occurred in the morning and all operations at Copler have been suspended as a result.

08:51 EST Puma inititates ALISCA-Lung1 Phase II trial of Alisertib in SCLC - Puma Biotechnology announced the initiation of its ALISertib in CAncer or ALISCA-Lung1, Phase II trial or PUMA-ALI-4201; NCT06095505, of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer. The ALISCA-Lung1 trial will enroll up to 60 patients with extensive stage small cell lung cancer who have progressed on or after first-line platinum-based chemotherapy and immunotherapy. Patients must provide tissue specimens so that biomarkers can be analyzed. Alisertib is dosed at 50 mg BID on days 1-7 of every 21-day cycle. The primary endpoint of the trial is objective response rate, with secondary endpoints of duration of response, disease control rate, progression-free survival and overall survival. Puma will also be looking at each of these endpoints within selected pre-specified biomarker subgroups and will assess whether there is enhanced efficacy in any biomarker subgroup. Puma will be performing its biomarker analysis of the ALISCA-Lung1 trial in parallel with the execution of the clinical trial. Puma plans to perform an initial interim analysis for the evaluation of the biomarkers as well as an evaluation of efficacy. Based upon the outcomes of the study, Puma anticipates meeting with the U.S. Food and Drug Administration to explore the potential for an accelerated approval pathway for alisertib in small cell lung cancer. "

08:48 EST Equus II Inc subsidiary Morgan E&P completes two horizontal wells - Equus Total Return announced that Morgan E&P, a wholly-owned subsidiary of Equus, has completed its first two wells in Billings County, North Dakota, the Baranko 1-28H and the Obrigewitch 1-33H. Both wells, along with construction of production facilities, were completed by the end of November. Morgan drilled both wells into their target zones of the Middle Bakken, with the Baranko achieving a total depth of 19,920 feet and the Obrigewitch achieving a total depth of 21,356 feet. The wells were completed with 60-stage fracture stimulations.

08:46 EST NeoVolta books over $1M in gross revenue for Q4 - NeoVolta booked over $1M in gross revenue for the fourth quarter, marking a tremendous 80% growth year-over-year with Gross Margins topping 20%, in a year where many feared the negative impacts of California's Net Energy Metering 4 on solar sales. "We experienced a strong rebound in revenue now that the impact of NEM3, which went into effect April 14, 2023, is being understood. New installers are being trained, and opportunities outside of California are being explored and courted," said Brent Willson, CEO at NeoVolta Inc. "Additionally, NeoVolta has seen a significant increase in solar installer applications for certifications in the past several months," Willson added.

08:45 EST Foremost Lithium announces start of drill program at Zoro Lithium Project - Foremost Lithium Resource & Technology confirmed that it has commenced drilling on it's Zoro Lithium Property located in the Snow Lake region of Manitoba. The Company has received a multi-year work permit for its Zoro Property from the Mining Permit Office of the Manitoba Government, valid until April 26th of 2026, which will improve future corporate administration flow, increase consistency with other application processes, and will ease future long-term drill and exploration programs on the property. This drill program has been partially funded from a $300,000 grant awarded to the Company by The Manitoba Mineral Development Fund in January of 2024. Jason Barnard, President and CEO of Foremost Lithium, said: "Our maiden resource at our Dyke 1 remains our high priority target with the potential for significant resource expansion beyond its current estimates. Given the fact that we have received a multi-year permit, we have time on our side to build tonnage and resource. Our Zoro Property has 16 proven spodumene bearing lithium pegmatite dykes. This is an ideal opportunity to get those drills turning and hit some great intersections to create great new catalysts for our Company and shareholders, regardless of current market conditions."

08:44 EST Reborn Coffee partners with pet fashion brand Sgt. Puppa - Reborn Coffee announced a strategic partnership with pet fashion brand Sgt. Puppa, to feature a specially curated selection of pet attire and accessories at the Reborn Pet Social Cafe set to open in Pasadena, CA in May 2024. Under the partnership agreement, the Reborn Pet Social Cafe, set to open in Pasadena in May 2024, will feature a specially curated selection of Sgt. Puppa's pet fashions and accessories alongside Reborn's renowned coffee offerings. "Our collaboration with Sgt. Puppa is a fusion of specialty coffee culture and pet companionship, curated to enhance social interactions," said Jay Kim, CEO of Reborn Coffee. "The enthusiastic response to our Reborn Pet Social Cafe announcement has motivated us to elevate this concept with Sgt. Puppa's exclusive product line, aiming to significantly boost sales. Our pop-ups have already started to generate high sales, indicating strong market demand and customer interest in this novel concept. The early success of these pop-up shops underscores the potential for this venture to become a significant revenue source, leveraging the highly engaged and lucrative pet owner demographic to boost sales further."

08:42 EST Real Good Food announces international expansion into Canadian Club Channel - The Real Good Food Company announced the national launch of its refrigerated burritos into the Canadian club channel - marking the Company's first international sales. Bryan Freeman, Executive Chairman of The Real Good Food Company, said: "Our mission is to make people's favorite foods more nutritious, and we are thrilled to launch our low carb burritos to consumers across Canada. This highly incremental distribution win addresses the demands of Canadian consumers, who have continuously requested we launch in their region. While we are starting our initial rollout in Canada with our burritos, we will seek to further grow the depth of our Canadian penetration with other products over time."

08:41 EST Marriott sees FY24 net rooms growth of 5.5%-6% - Comments taken from Q4 earnings conference call.

08:41 EST Protagenic completes first dose escalation step in Phase I trial of PT00114 - Protagenic Therapeutics announced a step forward in its mission to address stress-related neuro-psychiatric disorders. The company has completed the first dose escalation step in the Phase I safety clinical trial for PT00114, its pioneering brain peptide compound. The compound has been extensively tested in models of anxiety, depression, PTSD and addiction before entering its present clinical trial. Key Highlights: Safety Validation: PT00114 has demonstrated safety at a low dose of 125 micrograms in the initial cohort of patients, with zero reported adverse reactions among subjects. There were no injection site reactions nor any tolerability matters amongst the subjects over a 30-day observation period. Clinical Protocol Progress: This is a step in the ongoing Phase I/IIa trial, which is designed to evaluate both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD, and Generalized Anxiety Disorder. The company looks forward to welcoming additional cohorts into the trial. Comprehensive Approach: In addition to monitoring disease status, the trial incorporates biomarker assessments, including circulating cortisol levels, to gauge initial treatment response. Strategic Collaboration: Axiom Real-Time Metrics, a CRO/Data Analytics firm, is partnering with Protagenic in managing the clinical program. Expert Insights: Dr. Maurizio Fava, Principal Investigator in Protagenic's Phase I/IIa clinical trial, emphasized the urgent need for novel therapeutics in addressing stress-related disorders: "Stress-related disorders are at an all-time high, and I am excited by the possibility of a novel mechanism which may help a population of patients greatly in need of new therapeutics."

08:39 EST American Resources' Novusterra enters partnership with Kenai Defense - American Resources Corporation announced that their affiliated company, Novusterra announced that the United States Army will be using its patented technology to develop greater protection of sensitive technologies. Through this collaborative partnership between Novusterra, Texas Tech University, and under subcontract with Kenai Defense, the parties will further develop Novusterra's patents for the production of carbon nanostructures and graphene utilizing coal as its primary, low-cost feedstock for next-generation defense applications.

08:39 EST Palisade Bio provides corporate update, reiterated upcoming milestones - Palisade Bio provided a corporate update and reiterated upcoming milestones. Recent Highlights: The formation of the Company's Clinical Advisory Board and the appointments of preeminent Key Opinion Leaders, Bruce Sands, MD, MS and Floria Rieder, MD; The exercise of outstanding common stock warrants resulting in gross proceeds of $2.5 million; Presentation of positive preclinical data of lead asset, PALI-2108, at the 2024 Crohn's & Colitis Congress; and Receipt of the second milestone payment to our joint development partner, Giiant Pharma, from the US Crohn's and Colitis Foundation, through its Inflammatory Bowel Disease Ventures program. Upcoming Milestones: Ongoing IND/CTA-enabling tox studies; Complete nonclinical IND/CTA-enabling activities by the end of the third quarter of 2024; Submit initial IND/CTA prior to the end of 2024; and Initiate Phase 1a/b before the end of 2024.

08:37 EST SharpLink Gaming completes domestic merger with SharpLink Gaming - SharpLink Gaming announced that effective , February 13, 2024, SharpLink Israel has completed its previously announced change of jurisdiction of incorporation from Israel to the State of Delaware through an agreement and plan of merger with SharpLink Gaming. Pursuant to the Merger Agreement, which was approved by shareholders at an Extraordinary Meeting of Shareholders held on December 6, 2023, SharpLink Merger Sub Ltd., an Israeli company and a wholly owned subsidiary of SharpLink US, has merged with and into SharpLink Israel, with SharpLink Israel surviving the merger and becoming a wholly owned subsidiary of SharpLink US. SharpLink US's common stock will commence trading on the Nasdaq Capital Market under the same trading symbol, SBET, effective at the market open tomorrow, February 14, 2024. The new CUSIP number for SharpLink US' common stock is 820014108.

08:36 EST LPL Financial to acquire Atria Wealth Solutions, terms not disclosed - LPL Financial Holdings announced that the firm has entered into a definitive purchase agreement to acquire Atria Wealth Solutions, a wealth management solutions holding company headquartered in New York. Atria supports approximately 2,400 advisors and 150 banks and credit unions, managing approximately $100 billion of brokerage and advisory assets. Established in 2017, Atria operates a network of broker-dealer subsidiaries focused on supporting independent financial advisors and institutions nationwide. As part of the agreement, Atria will transition its brokerage and advisory assets currently custodied with its network of broker-dealers to the LPL platform. The broker-dealers include two with a focus on supporting banks and credit unions - CUSO Financial Services and Sorrento Pacific Financial - and five that support independent financial professionals - Cadaret Grant, NEXT Financial Group, SCF Securities, Western International Securities and Grove Point Financial. The purchase agreement was signed on Feb. 12, 2024. We expect to close the transaction in the second half of 2024, and the conversion is expected to be completed in mid-2025, subject to receipt of regulatory approval and other conditions.

08:35 EST HCA Healthcare promotes Michael McAlevey to chief legal, administrative officer - HCA Healthcare announced that Michael McAlevey, senior vice president and chief legal officer, will be promoted to executive vice president - chief legal and administrative officer.

08:33 EST Clever Leaves, Paradise Seeds develop, register genetic assets in Colombia - Clever Leaves announced that through its partnership with award-winning Dutch seed bank, Paradise Seeds, to develop and register high performance cannabis cultivars in Colombia, Clever Leaves will have exclusive license to cultivate some of these genetics, while Paradise will make other cultivars available to third parties for cultivation across Colombia and Latin America. The two companies have already begun rigorous selection, phenotyping, and agronomic trials of several Paradise varieties at Clever Leaves' facility in order to register market-leading cultivars for production and commercialization. "Our partnership with Paradise, a company renowned for strains that have won multiple awards-including the High Times Cup, Highlife Cup, and Plant of the Year-represents an immense opportunity to expand Clever Leaves' global footprint through the registration of Paradise's genetics. By combining Paradise's renowned strains with the knowledge and capabilities Clever Leaves has built in Colombia, we can strengthen our portfolio and export new strains to countries where medical cannabis is allowed," said Andres Fajardo, CEO of Clever Leaves.

08:32 EST Sientra to pursue sale of business through voluntary Chapter 11 process - Sientra filed for Chapter 11 protection in the United States Bankruptcy Court for the District of Delaware on February 12, 2024. The Company further disclosed that it intends to pursue a sale of its business under Section 363 of the Bankruptcy Code, while continuing to support its customers during the Chapter 11 process. The Company seeks to execute an expedited sale process. Sientra will utilize existing cash reserves and $22.5 million in new money debtor-in-possession financing from existing lenders to facilitate the sale and support ongoing Company operations. The debtor-in-possession financing will also include a "roll up" of $67.5 million of Sientra's prepetition debt obligations. The Company will continue to operate its business during this process.

08:31 EST Ensysce Biosciences announces exercise of warrants for $4.7M in gross proceeds - Ensysce Biosciences announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 3,601,752 shares of common stock of the Company originally issued in May 2023, having an exercise price of $3.637 per share, at a reduced exercise price of $1.31 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1. The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $4.7 million, prior to deducting placement agent fees and estimated offering expenses. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered warrants to purchase shares of common stock. The new warrants will be exercisable for an aggregate of up to 7,203,504 shares of common stock, at an exercise price of $1.06 per share and will be immediately exercisable upon issuance. 3,601,752 of the new warrants will expire on May 12, 2028, and 3,601,752 of the new warrants will have a term of eighteen months from the issuance date. The offering is expected to close on or about February 14, 2024, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for activities related to preparation for Phase 3 clinical studies for its lead agent PF614, to repay the remaining amounts on the debt incurred in October and November 2023, and for general corporate purposes.

08:29 EST Nano-X Imaging receives FDA clearance for HealthFLD - Nano-X Imaging announced that its deep-learning medical imaging analytics subsidiary, Nanox AI, received 510(k) clearance by the U.S. Food and Drug Administration for HealthFLD. HealthFLD is intended to support clinicians in the detection of fatty liver, correlated with hepatic steatosis, an early sign of metabolic dysfunction-associated steatotic liver disease, formerly referred to as non-alcoholic fatty liver disease. "We are proud to offer HealthFLD as the third product of Nanox AI's suite of cutting-edge, AI-powered population health solutions designed to confront chronic diseases of great public health concern head-on and potentially improve health outcomes," said Erez Meltzer, Chief Executive Officer of Nanox. "Furthermore, we believe that AI innovative solutions, and specifically HealthFLD, may deliver substantial advantages to the biopharmaceutical industry to streamline the identification of candidates for clinical trials of much-needed therapies for liver diseases including MASH. This regulatory decision solidifies our leadership as a developer of automated AI software medical devices."

08:28 EST 99 Acquisition Group, Nava Health enter merger agreement - Nava Health MD and 99 Acquisition Group have entered into a definitive merger agreement. Upon closing the proposed transaction, 99 Acquisition will be renamed Nava Health MD, Inc. and expects to remain listed on the Nasdaq Stock Market. Nava Health uses AI-powered technology, proprietary data and automation to drive the continuous optimization of Nava Health's backend systems, front end client support and medical outcomes. Nava Health's Customized Vitality Plans factor in medical history, proprietary Q&A data and advanced diagnostics to generate personalized treatment plans, reducing manual workload and empowering patients. Nava Health's revenue has grown from $6.7 million in 2021 to approximately $24.8 million in 2023. The revenue for 2023 grew approximately 81% when compared to 2022 revenue, with Adjusted EBITDA growth of approximately 173% in 2023. Additionally, Nava Health saw an approximate 62% increase in total appointments in 2023, with an approximate 12% increase in revenue per appointment. 99 Acquisition has entered into a Merger Agreement with Nava Health, dated February 12, 2024, pursuant to which 99 Acquisition will acquire 100% of the equity securities of Nava Health, with Nava Health becoming a wholly-owned subsidiary of 99 Acquisition. In exchange for their equity securities, the shareholders of Nava Health will receive an aggregate number of shares of common stock of 99 Acquisition having a total value equal to $320 million at the closing of the proposed transaction. The proposed transaction has been approved by the boards of directors of Nava Health and 99 Acquisition. The proposed transaction is subject to approval by the stockholders of 99 Acquisition and the shareholders of Nava Health, as well as the satisfaction or waiver of other customary closing conditions, including a registration statement on Form S-4 containing a proxy statement/prospectus being filed with and declared effective by the U.S. Securities and Exchange Commission. Any cash remaining on the combined company's balance sheet at the closing of the proposed transaction, after any potential shareholder redemptions and the settlement of transaction-related expenses, is expected to be utilized by the combined company for working capital, growth, and other general corporate purposes. The proposed transaction is expected to be completed in the second quarter of 2024.

08:25 EST Mangoceuticals offers one year supply of Mango ED to San Francisco players - Mangoceuticals will offer a free one-year supply of its "Mango" erectile dysfunction product to the San Francisco players and coaches to raise spirits following Sunday's Big Game loss, ensuring they can still perform in the bedroom after losing on the field. MangoRx is committed to helping men tackle hard issues. In addition to offering the losing team players the opportunity to score, fans can also get in on the fun with a special discount code equal to 3 free Mango pills, the game's point difference. Fans can use the code "SB58", now available through February 29, 2024.

08:23 EST Bayer, AskBio announce first patient randomized in Phase II gene therapy trial - Bayer AG and Asklepios BioPharmaceutical announced that the first patient has been randomized in GenePHIT, a Phase II trial of AB-1002 for the treatment of congestive heart failure. GenePHIT is an adaptive, double-blind, placebo-controlled, randomized, multicenter trial to evaluate the safety and efficacy of a single intracoronary infusion of AB-1002 in adults with non-ischemic cardiomyopathy and New York Heart Association Class III heart failure symptoms who have been medically stable for at least four weeks. This milestone in the development of AB-1002 for the treatment of CHF potentially brings this investigational therapy one step closer to treating patients with high unmet medical need.

08:22 EST Tonix Pharmaceuticals announces engagement of Rho as CRO - Tonix Pharmaceuticals announced that it has engaged Rho, a global contract research organization, CRO, to support Tonix's preparation and planned submission of its New Drug Application, NDA, to the U.S. Food and Drug Administration, FDA, for the approval of Tonmya for the management of fibromyalgia. "We are excited by our most recent positive Phase 3 study results of Tonmya and look forward to Rho's support in preparing our NDA," said Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals. "We intend to meet with the FDA in the first half of this year and to submit our NDA in the second half of the year. We believe we have completed all development work required for the NDA, including CMC requirements and the completion of two positive Phase 3 studies."

08:21 EST Genasys announces State of Utah's DOC selected Genasys Protect CONNECT - Genasys announced the State of Utah's Department of Corrections, DOC, has agreed to a multi-year contract for Genasys Protect CONNECT. "We are proud to support our critical law enforcement partners for the state of Utah," said Chief Jeff Halstead, CONNECT Director of Strategic Accounts. "CONNECT will provide the capacity to increase efficiency, improve the safety of DOC employees, and provide additional services to all DOC public safety partners."

08:19 EST El Pollo Loco appoints Liz Williams as CEO, Director - El Pollo Loco announced that its Board of Directors has appointed Elizabeth Williams as the Company's new Chief Executive Officer, CEO, and as a member of its Board of Directors, effective March 11, 2024. Williams will succeed Maria Hollandsworth, who has served as the Company's interim Chief Executive Officer since November 3, 2023. Hollandsworth has been appointed as President of El Pollo Loco and will also continue to serve as the Company's Chief Operating Officer. Most recently, Williams served as the Chief Executive Officer of Outfox Hospitality, parent company of Foxtrot, a high-growth modern cafe and convenience store, and Dom's Kitchen and Market.

08:18 EST Yoshitsu issues 2024 letter to shareholders - Yoshitsu announced that Mei Kanayama, the Principal Executive Officer of the Company, has issued a letter to shareholders highlighting the Company's recent accomplishments and plans for 2024. "As we embrace the post-pandemic resurgence of our business, it is my privilege to reflect on our journey and chart the course for an exhilarating 2024. The past year has been a transformative period for Yoshitsu, filled with both challenges and milestones that have shaped our journey. The year 2023 was a testament to our business resilience and adaptability... Our expansion into the United States and Europe through the establishment of Tokyo Lifestyle Holding Inc. in Delaware and REIWATAKIYA BOS LLC in Massachusetts, and the launch of our direct-sale store in Seattle and the REIWATAKIYA flagship store in London, marked significant milestones in our mission to bring the essence of Japanese craftsmanship to the global audience. Our financial performance in the first six months of fiscal year 2024 has been a testimony to our strategic progress and operational excellence....As we step into 2024, our vision is clear and our resolve is unwavering. We are poised to amplify our brand presence, particularly in the United States, Canada, and the United Kingdom, catering to the burgeoning global demand for premium Japanese products... Our primary focus in 2024 will be on brand expansion, particularly in the United States. We plan to open more flagship stores, offering an unparalleled shopping experience that showcases the essence of our brand... In line with our vision to weave our brand into the global fabric, we plan to fortify our alliances with renowned enterprises in 2024 to reinforce our sales network and catapult our brand to new heights. The coordinated forces are expected to amplify our market presence and enhance our brand influence worldwide, stocking up our resources to tap into new markets... As we embark on this exciting journey in 2024, I am confident that with our focus on strategic initiatives, dedication to innovation, and commitment to excellence, Yoshitsu is positioned well to reach new heights and achieve unprecedented success."

08:17 EST H&R Block to release reality TV parody series 'Responsibility Island' - H&R Block makes its debut in the entertainment world with the premiere of "Responsibility Island," a short format scripted reality TV series that brings levity to taxes. The comedic satire is comprised of four short episodes, featuring a dynamic and hilarious cast. All four episodes will air on Friday, Feb. 16, on The Roku Channel, YouTube or H&R Block's website. Responsibility Island features a group of young adults who think they are embarking on the latest dating show journey. To their surprise, what they thought would be an adventure to find true love is actually a responsibility boot camp. The show follows cast members TayTay, Jynyphr, Zane, Blaze, Trinity B and Narci as they take on a gauntlet of challenges in adulting designed to teach self-reliance and productivity. They must face the mother of all responsibility to get off the island - filing their own taxes.

08:16 EST Aligos Therapeutics enhances finance leadership team - Aligos Therapeutics announced the appointments of Jordyn Tarazi as Vice President, Investor Relations and Corporate Communications and Nikhil Aneja as Vice President, Finance, effective immediately. Previously, Jordyn served as the Head of Investor Relations at CohBar, Inc., a company focused on metabolic dysfunction-associated steatohepatitis and other inflammatory/fibrotic indications. Nikhil joins from CareDx, Inc., where he led a global accounting team and oversaw all aspects of financial reporting.

08:14 EST Smith & Nephew announces commercial launch of its AETOS Shoulder System - Smith+Nephew announces full commercial availability of its AETOS Shoulder System in the US, along with 510(k) clearance for its use with ATLASPLAN 3D Planning Software and Patient Specific Instrumentation for total shoulder arthroplasty. Total shoulder arthroplasty is one of the fastest growing segments in Orthopaedics with an estimated 250,000 procedures in the US by 2025.

08:13 EST Iveco Group, Politecnico di Torino enter collaboration agreement - The Politecnico di Torino and Iveco Group have signed a collaboration agreement aimed at developing shared research programmes in the mobility sector. Over the next three years, they will conduct studies and research in the cutting-edge field of commercial vehicle design, with a focus on sustainable innovation. The studies will focus on the contribution of digitalisation, aided by Artificial Intelligence algorithms, in the design of new, innovative propulsion systems to support the transition towards a more sustainable future. The partners have established goals for the collaboration in areas related to energy management and reducing environmental impact, which are achievable in joint research like this through the adoption of Life Cycle Assessment criteria and eco-design methodologies. A fundamental tool in support of the European Green Deal and environmental sustainability, LCA is a multi-criteria evaluation methodology capable of covering a wide variety of impacts associated with human health, ecosystem health and resource availability.

08:12 EST Pasithea Therapeutics opens enrollment in the U.S. for Phase 1 trial of PAS-004 - Pasithea Therapeutics announced the activation of four clinical trial sites in the United States. These U.S. clinical trial sites in Texas and Virginia are now open and actively enrolling patients. This announcement follows the approval from the U.S. Food and Drug Administration of the Investigational New Drug application for PAS-004, and FDA review of the protocol for the Company's Phase 1 multicenter, open-label trial of PAS-004 in patients with MAPK pathway-driven advanced solid tumors with a documented RAS, NF1 or RAF mutation or patients who have failed BRAF/MEK inhibition. The objective of the Phase 1 study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of PAS-004 as well as to evaluate the preliminary anticancer activity of PAS-004 and to define the preliminary recommended Phase 2 dose. The Company's clinical development plan for PAS-004 following the Phase 1 study is to begin a Phase 2 clinical trial in NF1 pediatric and adult patients as soon as safety and PK are established. Pasithea has selected Novotech as the clinical research organization for the Phase 1 trial and will be collaborating in the U.S. with NEXT Oncology, led by Dr. Anthony Tolcher M.D., along with Dr. Ildefonso Rodriguez M.D., acting as principal investigator for the San Antonio, TX site. There are also three other clinical trial sites in Eastern Europe that are expected to open in the coming months.

08:10 EST Chesapeake signs long-term LNG liquefaction offtake agreement - Chesapeake Energy, Delfin LNG and Gunvor Group through Gunvor Singapore, entered into a liquefied natural gas - LNG - export deal that includes executed Sales and Purchase Agreements for long-term liquefaction offtake. Under the SPA, Chesapeake will purchase approximately 0.5 million tons of LNG per annum from Delfin at a Henry Hub price and contract targeted start date in 2028 then deliver to Gunvor on an FOB basis with the sales price linked to the Japan Korea Marker for a period of 20 years. These volumes will represent 0.5 mtpa of the previously announced up to 2 mtpa HOA with Gunvor.

08:10 EST FDA grants Edgewise fast track designation for EDG-5506 to treat Duchenne - Edgewise Therapeutics announced that the U.S. Food and Drug Administration FDA has granted Fast Track designation for EDG-5506 for the treatment of Duchenne. EDG-5506 is an investigational orally administered small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies, including Duchenne and Becker muscular dystrophy Becker . The FDA previously granted EDG-5506 Orphan Drug Designation ODD for the treatment of Duchenne and Becker, Rare Pediatric Disease Designation RPDD for the treatment of Duchenne, and Fast Track designation for the treatment of Becker. "Every day is important for individuals living with Duchenne and their families, and we are pleased that the FDA granted Fast Track designation," said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise. "Our roster of regulatory designations granted to EDG-5506 highlights the urgent and critical need for new and better therapeutic options for people living with these rare and life-threatening muscle disorders."

08:09 EST CalciMedica: FDA clears IND application for Phase 2 trial of Auxora - CalciMedica announced the clearance of its Investigational New Drug application by the U.S. FDA for the company's lead product candidate, Auxora, a potent and selective small molecule inhibitor of Orai1-containing CRAC channels, to be evaluated in a Phase 2 trial in acute kidney injury with associated acute hypoxemic respiratory failure. CalciMedica expects to initiate the trial, named KOURAGE, in the first half of 2024 and data expected in 2025.

08:08 EST TPG reports total AUM $222B as of December 31, 2023 - Reports Q4 revenue $983.1M...Total assets under management of $222B as of December 31 an increase of 64% compared to $135 billion as of December 31, 2022 "Our strong fourth quarter financial results marked the completion of an outstanding year for TPG. We are entering 2024 with significant momentum and have a number of levers to drive continued growth across our firm," said Jon Winkelried, Chief Executive Officer. "Through both organic innovation and completing the acquisition of Angelo Gordon, we have substantially expanded the breadth of our business. We now manage more than $220 billion of assets across a broadly diversified set of strategies and continue to further our position as a scaled, differentiated investment firm." TPG has declared a quarterly dividend of $0.44 per share of Class A common stock to holders of record at the close of business on February 23, 2024, payable on March 8, 2024

08:06 EST SaverOne 2014 granted new US patent - SaverOne 2014 was awarded a new patent by the USPTO. The patent, titled System and Methods to Facilitate Safe Driving, was granted on January 30, 2024. The patent describes SaverOne's advanced algorithms and its selective blocking mechanism to prevent the driver from accessing distracting phone functionalities while the vehicle is in motion. With this new patent, SaverOne's patent portfolio comprises of 23 patents of which 10 are already granted in various jurisdictions and a further 13 additional patent applications in process.

08:04 EST Kroger to lower prices following merger with Albertsons Cos - Kroger announced that it will lower prices following its proposed merger with Albertsons Cos. The company stated that it lowered prices in previous mergers, that it invested over $125M to lower prices at Harris Teeter after its merger in 2014 and more than $100M to lower prices at Roundy's after its merger in 2016. Kroger will invest $500M to lower prices following the merger with Albertsons starting day one following the transaction close. Kroger will also invest $1.3B to improve Albertsons' stores following the merger.

07:47 EST 2U sinks after raising 'substantial doubt' about ability to continue - 2U reported last night that as of December 31, 2023, its cash, cash equivalents, and restricted cash totaled $73.4M, a decrease of $109.2M from December 31, 2022. As of December 31, 2023, the company's total debt was $904.7M. 2U stated in its earnings release, "The company expects that if it does not amend or refinance its term loan, or raise capital to reduce its debt in the short term, and in the event the obligations under its term loan accelerate or come due within twelve months from the date of its financial statement issuance in accordance with its current terms, there is substantial doubt about its ability to continue as a going concern." Shares of 2U are down 23% to 70c in premarket trading. Needham this morning downgrades the shares on balance sheet concerns.

07:39 EST Ocular Therapeutix announces firs subjects screened in Phase 3 trial of AXPAXLI - Ocular Therapeutix announced that the first three subjects have been screened and received their first aflibercept injection in the Phase 3 SOL-1 clinical trial of AXPAXLI for the treatment of wet age-related macular degeneration. The Company previously announced FDA agreement on its Special Protocol Assessment Agreement Modification on January 25th.

07:36 EST Nextech3D.AI secures $1.8M 3D modeling deal - Nextech3D.AI announced a significant $1.8M 3D modeling contract with a major enterprise client. This deal provides significant revenue for the Company to be delivered in 2024.

07:34 EST Avicanna obtains indication-specific drug registration with Trunerox - Avicanna announced the Company's first indication-specific drug registration for Trunerox issued by INVIMA, the Health Authority of Colombia. The Trunerox drug approvalwas issued by INVIMA, after a detailed process of verification of all legal, technical, and pharmacological requirements were fulfilled in accordance with Decree 677 of 1995 and other applicable regulations. The approval allows Avicanna to manufacture and commercialize Trunerox in Colombia with approved indications and claims associated to the treatment for seizures related to Lennox-Gastaut Syndrome and Dravet Syndrome. Lennox-Gastaut Syndrome and Dravet Syndrome are two of the various, rare epileptic disorders classified as epileptic encephalopathies. Trunerox is Avicanna's proprietary oral formulation with 10% cannabidiol and is manufactured with good manufacturing practices GMP at Altea Farmaceutica in Bogota, Colombia utilizing CBD manufactured at the Avicanna's majority-owned subsidiary Santa Marta Golden Hemp SAS.

07:33 EST G1 Therapeutics tumbles after DMC recommends Phase 3 trial continues - Shares of G1 Therapeutics are down $1.93, or 43%, to $2.55 in pre-market trading after the company announced last night that the independent Data Monitoring Committee, or DMC, recommended continuation of the pivotal Phase 3 PRESERVE 2 trial evaluating trilaciclib in combination with gemcitabine and carboplatin for the first line treatment of metastatic triple negative breast cancer, or mTNBC, to the final analysis. This final analysis evaluating Overall Survival, or OS, is estimated to occur in the third quarter of 2024 and will be conducted on the intent-to-treat, or ITT, population. "The DMC did not express any concerns regarding safety or recommend any other changes to the study. G1 remains blinded to all data as the early stopping criteria were not met during the interim analysis," the company stated. "We remain confident in the ability of trilaciclib to ultimately achieve the OS primary endpoint based on the robust survival benefit demonstrated in the prior randomized Phase 2 study, which continued to meaningfully increase over time as patients received subsequent therapies, as well as the increased statistical power for the final analysis of this pivotal study. While a positive interim analysis would have enabled us to bring this therapy to patients in need sooner, we look forward to completing the study and potentially making this meaningful new treatment option available to patients with this highly aggressive form of breast cancer as early as next year," added Jack Bailey, Chief Executive Officer at G1 Therapeutics.

07:32 EST Candel Therapeutics announces CAN-3110 received U.S. FDA FTD - Candel Therapeutics announced that the U.S. Food and Drug Administration, FDA, granted Fast Track Designation, FTD, for CAN-3110 -- a first-in-class, replication-competent herpes simplex virus-1 oncolytic viral immunotherapy candidate - for the treatment of patients with recurrent high-grade glioma to improve overall survival. "Receiving FDA Fast Track Designation for CAN-3110 reinforces the critical need to find effective treatment options for patients with recurrent HGG and further supports the potential of CAN-3110 to address the challenges that the standard of care and conventional therapies have failed to meet," said Paul Peter Tak, MD, PhD, FMedSci, President and CEO of Candel. "As recently published in Nature, a strong local and systemic anti-tumoral response and improved survival in patients with recurrent HGG was observed following a single injection of CAN-3110. We look forward to reporting additional data, including the potential benefits from multiple injections of CAN-3110, from the ongoing phase 1b clinical trial in the second half of 2024."

07:25 EST WT Blockhain Technology signs MOA for operations in Myanmar, Taiwan - WT Blockchain Technology Company, a subsidiary of Trans Global Group, signed a memorandum of authorization for operations in Myanmar and Taiwan. This also indicates that more and more countries and regions will start the operation of the WTAI system in the future, and work together for the new ecology of WTB. WTAI is a DAPP system independently developed by WT Blockchain Technology Company. The main function of the system is to provide stable investment and financial services for global cryptocurrency users. At the same time, users generate computing power by checking in daily and participating in financial management, and obtain varying amounts of WTB, ultimately establishing a community ecology on the WTB chain.

07:17 EST Medicenna Therapeutics announces first patient dosed in ABILITY-1 study - Medicenna Therapeutics announced the first patient dosed in the combination arm of the Phase 1/2 ABILITY study evaluating MDNA11, a long-acting, "beta-enhanced not-alpha" interleukin-2 super-agonist, with KEYTRUDA. The combination portion of the study is designed to evaluate the potential for a synergistic effect of MDNA11 with KEYTRUDA in patients with advanced solid tumors. Solid tumors represent 90% of all cancers and although CPI therapies have shown promising advances in some types of immunosensitive cancers, more than 70% of patients do not respond to or become resistant to such therapies. MDNA11, with its uniquely differentiating 'beta-enhanced not-alpha' features, continues to be a potential best-in-class next-generation IL-2 super-agonist for treatment of advanced solid tumors. Pre-clinical data published in JITC in 2022 demonstrated that mice receiving both, MDNA11 and checkpoint inhibitors achieved complete and sustained tumor control even after multiple rechallenges, demonstrating the capacity for MDNA11 to sensitize solid tumors to checkpoint blockade. The ABILITY-1 Study is actively recruiting patients with different types of recurrent or metastatic solid tumors at multiple sites in the USA, Canada, Australia, and South Korea and is expected to initiate patient enrolment in Europe. Preliminary results from both the monotherapy expansion and combination escalation and expansion arms of ABILITY-1 the study will be available in H1 and H2 2024.

07:15 EST Marriott CEO sees 'another year of solid growth' in 2024 - Anthony Capuano, President and CEO, said, "Our team delivered excellent results in 2023, as demand for our industry leading portfolio of properties and offerings around the world continued to grow. Full year global RevPAR rose 15 percent, net rooms grew 4.7 percent, and our fee-driven, asset-light business model generated record levels of cash. In the fourth quarter, worldwide RevPAR rose 7 percent. International RevPAR grew 17 percent, with particular strength in Asia Pacific and Europe. In the U.S. & Canada, fourth quarter RevPAR rose over 3 percent. Group revenue at our hotels increased 7 percent compared to the 2022 fourth quarter, driven by solid rate increases. While already significantly above 2019 levels, hotel leisure revenue rose again, up 2 percent. Business transient revenue at our hotels grew 3 percent from the year-ago quarter, with demand from large corporate customers continuing to make gains. Our development team had a stellar 2023, signing a record 164,000 organic rooms globally, including 37,000 rooms from our deal with MGM Resorts International, and our development pipeline reached a new high of roughly 573,000 rooms at year end. During the year, we added nearly 81,300 rooms to our distribution, with one in four organic rooms from conversions. The power of our unparalleled Marriott Bonvoy loyalty program continues to increase, with 196 million members at year end. We've continued to leverage our global portfolio and have expanded our co-brand credit card offerings, with 31 cards now across 11 countries. In 2023, global card spend increased a remarkable 11 percent over the prior year. In 2024, we expect another year of solid growth and significant shareholder returns. With normalizing RevPAR growth around the world, we anticipate a worldwide full year RevPAR increase of 3 to 5 percent and net rooms growth of 5.5 to 6 percent. We expect this should yield adjusted EBITDA of approximately $4.9 billion to $5.0 billion for the year and enable us to return $4.1 billion to $4.3 billion to shareholders after factoring in $500 million to purchase the Sheraton Grand Chicago."

07:14 EST Augmedix names Levy as new SVP of Engineering - Augmedix announced that Tomer Levy joined the company in January 2024 in the newly-created Senior Vice President, SVP, of Engineering role. Prior to joining Augmedix, Levy most recently served as Senior Vice President of Research and Development at Change Healthcare.

07:13 EST Cigna and HelloFresh partner to expand access to healthy meal choices - Cigna's health benefits division Cigna Healthcare and HelloFresh, a meal kit company, announced an exclusive collaboration to offer discounted access to HelloFresh's meals to as many as 12 million Cigna Healthcare customers through their employers. The two companies will also team up to support HelloFresh's Meals with Meaning program, a social impact initiative that provides free meal kits for individuals experiencing food insecurity in local communities. Cigna Healthcare employer clients can choose from a variety of HelloFresh offerings with no minimum purchase amount. Employees can then choose among the options provided, which may include e-gift cards for employees, discounted meal kit subscriptions, and one-time box deliveries with no subscription required.

07:12 EST Marriott reports Q4 comparable systemwide constant dollar RevPAR up 7.2% - Fourth quarter 2023 comparable systemwide constant dollar RevPAR increased 7.2% worldwide, 3.3% in the U.S. & Canada, and 17.4% in international markets, compared to the 2022 fourth quarter.

07:09 EST LianBio board declares special cash dividend of $4.80 per share - The Board has declared a special cash dividend of $4.80 per ordinary share, including ordinary shares represented by ADSs, for an aggregate cash dividend amount of approximately $528 million. The special dividend is payable to holders of record of the Company's ordinary shares and ADSs as of the close of business on February 27, 2024. The Company expects to pay the dividend to its holders of record of ordinary shares on or about March 11, 2024. Citibank, the Depositary of the ADSs, will coordinate payment of the dividend to the holders of record of the Company's ADSs, net of applicable Depositary fees of US$0.05 per ADS held and applicable taxes, and expects to pay the dividend on March 14, 2024. The ex-dividend date for the ADSs for the special dividend will be the first trading day following the payment date. Holders of record of ADSs on the record date who sell their ADSs prior to the ex-dividend date will not receive the special dividend. In connection with the special cash dividend, the Depositary will close the books to ADS issuances and ADS cancellations at the close of business in New York City on February 20, 2024. The Depositary will re-open the books for ADS cancellations at the close of business in New York City on March 18, 2024. The applicable Depositary fees will apply for all ADS issuances and ADS cancellations.

07:08 EST LianBio to commence wind down of operations, sale of remaining assets - LianBio announced that the Company's Board of Directors had completed its comprehensive strategic review of the Company and determined to initiate the wind down of its operations, including the sale of remaining pipeline assets, the delisting of its American Depositary Shares, each representing the right to receive one ordinary share, from the Nasdaq Global Market and deregistration under Section 12(b) of the Securities Exchange Act of 1934 and workforce reductions. The Company currently anticipates a substantial portion of the wind down activities, including fulfillment of transition service obligations under its existing agreements and gradual cessation of currently active clinical trials, will be completed by the end of 2024. In parallel with the wind down of operations, the Board has declared a special cash dividend in the amount of $4.80 per ordinary share, including ordinary shares represented by ADSs, for an aggregate cash dividend amount of approximately $528 million. In accordance with the strategic review, the following actions will be taken: Wind Down and Workforce Reduction: LianBio will begin to wind down operations immediately and intends to pursue the sale of its remaining pipeline assets as part of the wind down process. To the extent such sales are successful, the Company expects to distribute any profits from the sales to its then-current shareholders in a subsequent distribution before the final dissolution of the Company. However, there is no guarantee that any shareholder's original investment, or any material amount, will be recovered. With reduced operations, the Company expects to reduce its workforce by over 50 full-time employees, or approximately 50% of the Company's current employee base, in the first quarter of 2024. Additional workforce reductions will occur over the course of 2024 following the transition of assets to partners and the fulfillment of the Company's transition services obligations. The Company will maintain a core group of employees necessary to implement an orderly wind down of the Company and support its efforts to maximize the value of the Company's remaining business and assets. LianBio expects that the full wind down of operations, including the sale of remaining assets or termination of licenses, as well as the termination of employees necessary to complete an orderly wind down, will be substantially complete by the end of 2024, with the complete dissolution expected to occur during the first half of 2027. The Company expects to meet its ongoing operational costs through funds retained after the special dividend. On February 13, 2024, the Company, pursuant to an authorization by the Board, provided notice to Nasdaq that it intends to file a Form 25 with the U.S. Securities and Exchange Commission on or about March 8, 2024 to effect the voluntary delisting of the Company's ADSs from Nasdaq and to deregister the ADSs under Section 12(b) of the Exchange Act. As a result, the Company currently expects that the last day of trading on Nasdaq will be on or about March 18, 2024, when Form 25 takes effect. Ninety days thereafter, the deregistration of the Company's ADSs under Section 12(b) of the Exchange Act is expected to become effective. Following the delisting of the Company's ADSs from Nasdaq, the Company intends to file a Form 15 with the SEC certifying that it has fewer than 300 shareholders of record, upon which the Company's filing obligations under the Exchange Act will immediately be suspended, including the obligations to file all periodic reports. Following the delisting, any trading in the Company's ADSs would only occur in privately negotiated sales and potentially on an over-the-counter market. The Company expects that its ADSs will be quoted on a market operated by OTC Markets Group so that a trading market may continue to exist for its ADSs. There is no guarantee, however, that a broker will continue to make a market in the ADSs and that trading of the ADSs will continue on an OTC market or otherwise. The Board believes that the decision to delist the ADSs from the Nasdaq and deregister and suspend its reporting obligations under the Exchange Act is in the best interests of the Company and the holders of its ordinary shares and ADSs. As the Company undertakes steps to wind down operations and return value to the shareholders through its asset sales, out-licensing efforts and the payment of dividends, the Board has determined that the burdens associated with operating as a registered public company outweigh any advantages to the Company and its holders of ordinary shares and ADSs. The Board's decision was based on careful review of numerous factors, including the potential for curbing the significant costs associated with preparing and filing periodic reports with the SEC and the legal, audit and other expenses associated with being a reporting company, as well as the substantial costs and demands on management's time under the Sarbanes-Oxley Act of 2002, SEC rules and Nasdaq listing standards.

07:08 EST USA Compression sees 2024 net income $95M-$115M - Sees 2024 adjusted EBITDA $555.0M-$575.0M.

07:06 EST Shopify reports Q4 GMV up 23% to $75.1B - Gross Payments Volume grew to $45.1B, representing 60% of GMV processed in the quarter, versus $34.2 billion, or 56%, for the fourth quarter of 2022.

07:06 EST Coca-Cola reports Q4 global unit case volume up 2%, up 2% for FY

07:04 EST Moody's: Noemie Heuland will join as Chief Financial Officer - Moody's (MCO) Names Noemie Heuland as Chief Financial Officer....Ms. Heuland brings nearly 25 years of financial leadership experience at large public companies in the finance and technology spaces. She joins Moody's from Dayforce (DAY, formerly Ceridian) here she has served as Executive Vice President and CFO since 2020. Prior to Dayforce, Ms. Heuland spent 12 years with global enterprise application software provider SAP, during which time the company experienced extraordinary growth as it transitioned to a global software as a service SaaS business model.

06:42 EST Hasbro falls 12% to $45.11 after Q4 results miss estimates

06:39 EST Clean Energy makes strategic $10M investment in Rimere - Clean Energy Fuels closed a $10M strategic investment in Rimere, a climate solutions company with proprietary plasma technology. The funding will accelerate development and field testing of Rimere's two independent devices, the Reformer and the Mitigator, that reduce climate change emissions and enable the use of natural gas to accelerate the transition to a clean hydrogen future. The Reformer uses proprietary sequential hybrid plasma technology to transform natural gas into clean hydrogen and high-quality graphene, without creating any CO2 emissions. The Mitigator is a plasma thermal oxidizer that reduces the greenhouse gas potency of fugitive methane emissions. Rimere is currently an equity method investee of Clean Energy and has raised $18.25M of committed capital to date since its formation in 2020.

06:37 EST KalVista says 3 KONFIDENT trial met all endpoints - KalVista Pharmaceuticals announced positive results from the phase 3 KONFIDENT clinical trial demonstrating statistically and clinically significant efficacy of sebetralstat as oral on-demand therapy for hereditary angioedema. KONFIDENT was the largest and most representative trial ever conducted in HAE, and included adolescents, patients using long-term prophylaxis, and all attack severities and locations. The clinical trial met all primary and key secondary endpoints and demonstrated a favorable safety profile. HAE attacks treated with both 300 mg and 600 mg of sebetralstat achieved the primary endpoint of beginning of symptom relief significantly faster than placebo. The median time to beginning of symptom relief was 1.61 hours with sebetralstat 300 mg, 1.79 hours with sebetralstat 600 mg, and 6.72 hours with placebo. Consistent with previous studies, sebetralstat was well-tolerated, with a safety profile similar to placebo. There were no patient withdrawals due to any adverse event and no treatment-related serious adverse events were observed. Treatment-related adverse event rates were 2.3% for 300 mg sebetralstat, 2.2% for 600 mg sebetralstat, and 4.8% for placebo.

06:33 EST Hasbro CFO says 2023 'not without some challenges' - "Guided by our strategy of "Fewer, Bigger, Better," we had important wins across both toys and games while making progress in our transformation during a challenging 2023. Despite the macroeconomic backdrop, we are entering 2024 with a healthier balance sheet, a leaner cost structure, and a diverse portfolio of industry-leading toy and game brands that support our capacity to invest in the business and maintain our commitment to returning cash to shareholders via our category-leading dividend," said Chris Cocks, Hasbro CEO. "Our refreshed leadership team is bringing innovative new products to our fans. At the same time, we are taking the necessary actions to transform Hasbro and deliver long-term profitable growth starting with driving significant profit growth across our segments in 2024 and building momentum in our innovation pipeline between now and 2025." "2023 was a productive year for Hasbro, although not without some challenges." said Gina Goetter, Hasbro CFO. "As we navigated the current environment, we took aggressive steps to optimize our inventory, reset the cost structure, and sharpen our portfolio focus on play with the eOne film and TV divestiture. Taken together, the actions throughout the full year have positioned the company for improved financial performance in 2024 and beyond. We are encouraged by our recent progress and remain laser focused on execution to deliver on our transformation objectives."

06:19 EST Gryphon Digital Mining produces 58 bitcoin-equivalent coins in January - Gryphon Digital Mining has released its operational update for January. Key highlights for the month: Produced approximately 58 bitcoin-equivalent coins; recorded bitcoin efficiency of 68 BTC/EH; company record average self-mining hashing power of 864 PH/s; total attributable hashing power of about ~1.3 EH/s. During January, Gryphon mined approximately 58 bitcoin-equivalent coins while posting a company record average self-mining hashing power of 864 PH/s and total attributable hashing power of approximately 1.3 EH/s. The month's performance translated into a bitcoin efficiency rating of 68 BTC/EH.

06:15 EST AT&T, FirstNet announce 10-year investment to expand public safety network - The FirstNet Authority and its network partner, AT&T, are announcing an investment in the future of public safety communications. The FirstNet Authority's 10-year, $8B investment initiative will evolve and expand FirstNet - America's public safety network. The FirstNet Authority plans to invest $6.3B through its network contract with AT&T and anticipates an additional $2B for ongoing investments in coverage enhancements for public safety, which is currently under discussion by the parties. These strategic investments will expand and evolve FirstNet so public safety stays at the forefront of innovative, lifesaving technologies. This landmark announcement launches the next phase of FirstNet with a 10-year investment initiative that will: Provide first responders on FirstNet with always-on priority and preemption across all AT&T 5G commercial spectrum bands, starting in March. Build thousands of new, purpose-built FirstNet cell sites across the country - including 1,000 new sites within the next two years. Beyond the initial $6.3B investment, the FirstNet Authority anticipates additional investments over the next decade to deliver Band 14 coverage enhancements. These coverage investments will reflect public safety factors and network considerations, all in support of public safety response operations. Create a standalone 5G core to enhance current 5G functionality with specific public safety features on FirstNet and support the transition of public safety's Band 14 spectrum from LTE to 5G. Expand mission-critical services - voice, video, data, and location - to complement public safety's localized, voice-only radio systems with reliable, wireless connectivity. Upgrade public safety's dedicated fleet of deployable network assets with 5G connectivity to improve operational safety, security, and resiliency. Ready the network to evolve beyond 5G, while remaining focused on public safety's unique needs and emerging requirements when implementing future technological advancements.

06:07 EST Shattuck Labs enters license agreement with Ono Pharmaceutical - Shattuck Labs (STTK) announces a worldwide drug discovery collaboration with Ono Pharmaceutical (OPHLY) to generate novel bifunctional fusion proteins targeting certain pathways in autoimmune and inflammatory diseases. Under the terms of the agreement, Shattuck will receive an up-front payment and be eligible for success-based licensing, regulatory, and commercial milestone payments with a total value of up to $227M, as well as tiered royalties based on global net sales. Shattuck will lead discovery research of certain prespecified compounds directed toward a pair of targets selected by Ono from Shattuck's pipeline of bifunctional fusion proteins, and Ono will cover all of Shattuck's associated research and development expenses. Shattuck granted to Ono an exclusive option to develop and commercialize multiple products resulting from the collaboration agreement. Following an option exercise, Ono will be responsible for further development and commercialization worldwide.

06:03 EST Hercules Capital announces new supplemental cash distribution of 32c per share - Hercules Capital is pleased to announce that its Board of Directors has declared a new supplemental cash distribution of 32c per share, to be distributed equally over four quarters beginning with an 8c per share distribution for the fourth quarter of 2023. The record date is February 28 with payment date of March 6. This 8c supplemental cash distribution is in addition to the previously announced regular quarterly cash distribution that Hercules declared for the fourth quarter of 2023 of 40c per share.

05:54 EST Microsoft plans Xbox business update event for February 15 - Microsoft is planning an Xbox business update event on February 15 at 3PM ET, delivered via a podcast hosted by Xbox's Phil Spencer, Sarah Bond, and Matt Booty, Xbox said via X, the platform formerly known as Twitter. Reference Link

05:23 EST Roche enters collaboration agreement with PathAI to develop pathology algorithms - Roche announced that it has entered into an agreement with PathAI. Under the terms of this agreement, PathAI will exclusively work with Roche Tissue Diagnostics, or RTD, to develop AI-enabled digital pathology algorithms in the companion diagnostics space. RTD will work exclusively with PathAI for a pre-specified term as the sole external algorithm development company for AI-powered companion diagnostics, while retaining the ability to continue to develop its own algorithms for companion diagnostics. PathAI will retain the ability to freely develop algorithms outside of companion diagnostics. Under a previous agreement from October of 2021, the companies jointly developed an embedded image analysis workflow for pathologists. This workflow allows PathAI image analysis algorithms to be accessed within Roche's navify Digital Pathology software platform. PathAI algorithms were the first to be fully integrated into the Roche Open Environment.

05:17 EST Ericsson provides 5G core network to Swedish Civil Contingencies Agency - The Swedish Civil Contingencies Agency, or MSB, has procured a 5G core network from Ericsson to develop Rakel G2, Sweden's critical communications network for public safety and emergency services including national defense purposes.

05:10 EST Cedar Fair to hire 1,600 seasonal associates - Valleyfair said it plans to hire more than 1,600 seasonal associates as it prepares to open for the 2024 season in May. The park anticipates filling the majority of those roles during a week-long hiring blitz to be held February 17-24 as part of one of the largest-ever recruiting campaigns by Cedar Fair, across all its parks in the United States and Canada.